Ignite Creation Date:
2024-05-06 @ 3:47 AM
Last Modification Date:
2024-10-26 @ 11:39 AM
Study NCT ID:
NCT02375997
Status:
UNKNOWN
Last Update Posted:
2015-03-03
First Post:
2014-10-27
Brief Title:
Early Palliative Care in Metastatic Esophageal Squamous Carcinoma ESCC and Gastric Cancer
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Metastatic Esophageal Squamous Carcinoma ESCC and Gastric Cancer
Status:
UNKNOWN
Status Verified Date:
2015-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The majority of patients with newly diagnosed metastatic ESCC and gastric cancer patients experience a number of physical and psychosocial symptoms related to their cancer Those patients endure the greatest level of distress from their disease relative to other cancer populations in China Although new drugs have been applied in recent years the median overall survival time of metastatic ESCC and GC patients are still around 12 months Therefore it is essential to maximize their quality of life QOL from the time of diagnosis Multiple studies demonstrate that symptoms such as pain fatigue and anorexia are prevalent at diagnosis and worsen over time As a result suffering increases throughout the course of the illness To be most effective palliative care with intensive symptom management and psychosocial support should begin at the time of diagnosis not once life-prolonging therapies have failed And some studies have revealed that early palliative can even prolong the overall survival time in advanced lung cancer The investigators then initiated a randomized phase III clinical trial with standard oncology care plus early palliative care or not in metastatic esophageal carcinoma and gastric cancer to observe whether the early palliative can improve the QOL and even prolong the overall survival time in those patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None